2/3/2022, 12:31 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Merck & Co Inc

Merck's sales up by 24% to $13.52 billion in Q4

Merck & Co., Inc. announced on Thursday that its worldwide sales in the fourth quarter of the fiscal year 2021 stood at $13.52 billion, up by 24% in comparison to the same period the previous year, exceeding expectations. The company's net income came in at $3.82 billion, improving from the net loss of $2.62 billion registered in the same trimester in 2020. Its diluted earnings per share (EPS) were $1.51 per share, ameliorating from losses per share of $1.03 recorded in that period the year before. Meanwhile, in the entire 2021, Merck's sales grew by 17% year-on-year to $48.7 billion.

"Throughout 2021, we invested in the discovery, development, production and commercialization of medicines and vaccines, furthering the sustainability of our business," the firm's Chief Executive Officer (CEO) and President Robert M. Davis said. "We enter 2022 with strong momentum and are moving with speed to bring forward innovations that address critical unmet needs and contribute to global health."

Following the release of the report, Merck's shares advanced by 0.93% in premarket trading.

Baha Breaking News (BBN) / JR